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AbstrACt
Introduction Jaundice caused by hyperbilirubinaemia 
is a physiological phenomenon in the neonatal period. 
However, severe hyperbilirubinaemia, when left untreated, 
may cause kernicterus, a severe condition resulting in 
lifelong neurological disabilities. Although commonly 
applied, visual inspection is ineffective in identifying 
severe hyperbilirubinaemia. We aim to investigate 
whether among babies cared for in primary care: (1) 
transcutaneous bilirubin (TcB) screening can help reduce 
severe hyperbilirubinaemia and (2) primary care-based 
(versus hospital-based) phototherapy can help reduce 
hospital admissions.
Methods and analysis A factorial stepped-wedge cluster 
randomised controlled trial will be conducted in seven 
Dutch primary care birth centres (PCBC). Neonates born 
after 35 weeks of gestation and cared for at a participating 
PCBC for at least 2 days within the first week of life are 
eligible, provided they have not received phototherapy 
before. According to the stepped-wedge design, following 
a phase of ‘usual care’ (visual assessment and selective 
total serum bilirubin (TSB) quantification), either daily 
TcB measurement or, if indicated, phototherapy in the 
PCBC will be implemented (phase II). In phase III, both 
interventions will be evaluated in each PCBC. We aim to 
include 5500 neonates over 3 years. Primary outcomes 
are assessed at 14 days of life: (1) the proportion of 
neonates having experienced severe hyperbilirubinaemia 
(for the TcB screening intervention), defined as a TSB 
above the mean of the phototherapy and the exchange 
transfusion threshold and (2) the proportion of neonates 
having required hospital admission for hyperbilirubinaemia 
treatment (for the phototherapy intervention in primary 
care).
Ethics and dissemination This study has been approved 
by the Medical Research Ethics Committee of the Erasmus 
MC Rotterdam, the Netherlands (MEC-2017-473). Written 
parental informed consent will be obtained. Results from 
this study will be published in peer-reviewed journals and 
presented at (inter)national meetings.
trial registration number NTR7187.
IntroduCtIon   
In newborns, severe hyperbilirubinaemia may 
cause brain damage when it is not recognised 
or is left untreated.1 2 This spectrum of neuro-
logical sequelae is called kernicterus spec-
trum disorder (KSD), with acute bilirubin 
encephalopathy and its consequences at the 
extreme end, and more subtle disorders at 
the other.1 3 KSD also encompasses ‘classical 
kernicterus’, a chronic, irreversible, neuro-
pathological disorder involving neuromotor 
dysfunction, auditory disorders and oculo-
motor impairments.1–4 
In high income countries, an estimated 1 
in 67 000 neonates develop classical kernic-
terus.5 6
Timely recognition of potentially 
severe jaundice, caused by hyperbiliru-
binaemia, is essential to prevent KSD.7 8 
strenghts and limitations of this study
 ► This study is the first randomised controlled trial 
(RCT) to assess the (cost) effectiveness of transcuta-
neous bilirubin measurement as a universal screen-
ing tool for potentially severe jaundice, addressing 
a knowledge gap highlighted in several national 
guidelines.
 ► This study is also the first  RCT to assess the 
(cost)  effectiveness of phototherapy outside the 
hospital setting.
 ► The stepped-wedge design of this study allows 
all participating primary care birth centres to have 
introduced both interventions as standard care to-
wards the end of the study, which will aid imple-
mentation if (cost) effectiveness of the interventions 
is demonstrated.
 ► A limitation is that parents and care providers can-
not be blinded to allocation of the interventions.
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Traditionally, jaundice is identified via visual inspec-
tion by maternity care professionals, midwives or 
parents. If potentially severe jaundice is suspected, 
total serum bilirubin (TSB) is quantified in blood 
taken via a skin prick to assess the need for treat-
ment.9 However, visual inspection of neonatal 
jaundice is proven to be inaccurate in detecting 
hyperbilirubinaemia10 11 and, therefore , ineffective 
in preventing kernicterus.12
Guidelines in several high-income countries advise 
universal screening for jaundice in newborns using TSB 
or transcutaneous bilirubin (TcB) measurement.10 13 
Several observational studies have shown a good correla-
tion between TSB and TcB measurements in the neonatal 
period.14 15 A programmatic evaluation of a TcB-based 
screening programme in Canada demonstrated a 55% 
reduction in severe hyperbilirubinaemia and related 
healthcare utilisation as compared with visual inspection 
plus selective TSB quantification.16 Similar findings were 
obtained in a retrospective multicentre study evaluating a 
screening programme using standard versus selective TSB 
or TcB measurement in the USA.17 Universal screening 
for neonatal jaundice in the primary care setting has the 
potential to reduce the incidence of severe hyperbiliru-
binaemia.2 18 This would also bring down the number 
of patients who require exchange transfusion which is a 
highly invasive treatment that carries significant health 
risks and substantial costs.
Hyperbilirubinaemia is usually treated with photo-
therapy in a hospital setting which may be applied via 
various modalities.2 Fibreoptic phototherapy using an 
underneath device (ie, mattress) is effective in reducing 
TSB levels, is safe,19 and meets existing guidelines.9 There 
is some evidence to suggest that fibreoptic phototherapy 
may safely and effectively be used in the primary care 
setting as well.14 20 21 The institution of phototherapy 
in the primary care setting may reduce the number of 
neonates admitted to hospital for hyperbilirubinaemia 
treatment and reduce associated costs.22
Whereas universal TcB screening for neonatal hyper-
bilirubinaemia and phototherapy provided in primary 
care have the potential to be effective and cost-effective 
via reducing the incidence of severe hyperbilirubinaemia 
and the need for hospitalisation.14 23 Evidence to support 
these assertions is currently lacking, while in today’s 
healthcare arena cost-effectiveness considerations are 
becoming increasingly important.
We hypothesise that non-invasive screening for 
neonatal hyperbilirubinaemia using TcB and application 
of phototherapy in primary care will (cost) effectively 
reduce the incidence of severe hyperbilirubinaemia 
and the need for hospital admission for hyperbiliru-
binaemia treatment. Here, we present our protocol for a 
factorial stepped-wedge cluster randomised controlled 
trial (RCT) among newborns cared for in primary care 
to test these hypotheses.
MEthods And AnAlysIs
study design
We will conduct a factorial stepped-wedge cluster RCT in 
seven primary care birth centres (PCBCs) in the Neth-
erlands to evaluate among newborns the effectiveness of 
(1) screening for hyperbilirubinaemia using daily TcB 
quantification to reduce the incidence of severe hyper-
bilirubinaemia and (2) treatment of hyperbilirubinaemia 
(if indicated) using phototherapy instituted within the 
PCBC to reduce the need for hospital admission. Accord-
ingly, each PCBC will start with (1) a control phase in 
which usual care is evaluated, followed by (2) a second 
phase in which one of both interventions is evaluated, 
followed by (3) a final phase in which both interventions 
are evaluated in parallel. More detail is provided below.
dutch perinatal care system
In the Netherlands, a significant proportion of women 
(30% in 2016) give birth in a primary care setting (ie, at 
home or in a PCBC) under the supervision of a commu-
nity midwife.24 In addition, many who deliver in a hospital 
setting are discharged home or to a PCBC within 24 hours 
after delivery. Maternity care assistants provide maternity 
care when the neonate and the mother are at home or in 
a PCBC, under the supervision of the community midwife 
(who will visit at least three times in the first week).25 Only 
healthy neonates will be cared for at home or in a PCBC 
(ie, neonates with congenital infection or other diseases 
will receive initial treatment in the hospital). The commu-
nity midwife will consult the paediatrician of an affiliated 
nearby hospital if a potential clinical problem such as 
hyperbilirubinaemia presents in the neonate. Neonates 
with a gestational age (GA) above 35 weeks who have 
been discharged from the hospital are especially at risk of 
developing severe unconjugated hyperbilirubinaemia.26
Participants
Study sites
This study will be performed in seven PCBCs in the Neth-
erlands. In these PCBCs altogether approximately 5000 
neonates and their mothers are admitted for at least 
48 hours each year. Each of the five largest PCBCs will be 
considered a cluster in the context of our cluster RCT. 
The two smallest PCBCs will be paired and will form a 
cluster together. A PCBC was selected for the study if it 
facilitated provision of maternity care during the first days 
post partum (that is, some PCBCs only facilitate deliveries 
and do not provide care beyond the first 24 hours after 
delivery).
Patient eligibility
Neonates are eligible for inclusion in the study if:
 ► The neonate was born after 35 completed weeks of 
gestation. Note: only neonates with a GA of 37 weeks 
or higher are born in primary care; nevertheless, a 
neonate may be eligible when born in the hospital 
between 35 and 37 weeks of GA and then discharged 
to a PCBC within 7 days after birth.
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 ► The neonate is admitted to a participating PCBC 
within the first week of life.
 ► The neonate is expected to remain admitted for at 
least 2 days (to allow for serial TcB measurements to 
take place).
 ► Signed informed consent (IC) is provided by parent(s) 
or primary caregiver(s).
Neonates are not eligible if:
 ► The neonate received phototherapy previously or 
is currently receiving phototherapy (reliability of 
TcB measurement is reduced in neonates who are 
receiving or have received phototherapy).14
 ► Parents do not have sufficient understanding of the 
Dutch language to be able to comprehend the patient 
information sheet and questionnaire.
Interventions and control
In this study, two interventions will be assessed in a 
2×2 factorial design to determine the effectiveness of each 
intervention separately. The timing of the implementa-
tion of each intervention will be allocated at the PCBC 
level.
Control group: usual care
During this initial study phase, usual care will be eval-
uated. Accordingly, visual inspection is used to identify 
jaundice, as advised in the Dutch national guideline for 
neonatal hyperbilirubinaemia.9 When potentially severe 
jaundice is suspected, a skin prick will be performed to 
determine TSB. The TSB level will be plotted on the 
Dutch nomogram27 (which is similar to the nomogram 
of the American Academy of Pediatrics and explained in 
box 1) and be discussed with the affiliated paediatrician, 
according to local procedures. If treatment for hyperbili-
rubinaemia is indicated, as judged by the affiliated paedi-
atrician, the neonate will be admitted to the hospital for 
this purpose.
Intervention 1: TcB measurement as a non-invasive screening tool
During the study phase in which this intervention is 
tested, TcB will be measured daily starting from 24 hours 
of age using the Dräger JM-105, a CE-marked and vali-
dated hand-held bilirubinometer, in all included 
neonates admitted to a PCBC allocated to this interven-
tion.28–31 If TcB exceeds the phototherapy threshold, as 
determined by the Dutch TSB nomogram for neonates 
born after 35 weeks of gestation,9 TSB will be quantified. 
Because the nomograms were originally designed to be 
applied to the TSB measurements and because the TcB 
measurements have an inaccuracy of maximally 50 
µmol/L (ie, 2.9 mg/dL),14 32 TSB will also be quantified if 
TcB is less than 50 µmol/L below the phototherapy treat-
ment threshold. The TSB level obtained will be discussed 
with an affiliated paediatrician (of the nearby hospital) 
in order to determine the need for phototherapy, again 
based on the Dutch nomogram.9 A second TcB measure-
ment on the same day may be performed at the discretion 
of the maternity care professional (eg, if the TcB level is 
close to the threshold for measuring TSB).
Following institution of phototherapy, bilirubin levels 
will be monitored using TSB rather than TcB given the 
reduced reliability of TcB in neonates receiving or having 
received phototherapy.14
Intervention 2: phototherapy in the PCBC 
During this study phase, the default location for appli-
cation of phototherapy, if clinically indicated, will be 
the PCBC, rather than the hospital. The indication for 
phototherapy is made by a paediatrician in the affiliated 
hospital based on the TSB level, according to the Dutch 
nomogram.9 Phototherapy in the PCBC will be provided 
using GE Healthcare BiliSoft Large, a commercially avail-
able, CE-marked and validated phototherapy mattress 
using blue LED-light.33 This phototherapy mattress is 
suitable for application in primary care as well as in the 
hospital setting.
The affiliated paediatrician will decide whether other 
blood tests have to be performed to determine the cause 
of hyperbilirubinaemia and at what time points follow-up 
TSB measurements need to be taken. Based on the 
results of these TSB measurements (dis)continuation 
of phototherapy and further follow-up is determined by 
the affiliated paediatrician. The affiliated paediatrician 
may decide to admit a neonate to the hospital for further 
hyperbilirubinaemia treatment at any time if there are 
strong reasons to do so; these reasons will be recorded. 
Phototherapy will not be applied in the PCBC in neonates 
who have hyperbilirubinaemia above the phototherapy 
threshold within 24 hours after birth, since this is consid-
ered to represent a likely pathological cause of hyperbil-
irubinaemia and bilirubin levels may rise swiftly in these 
neonates.9
Each PCBC will start with a time period without any 
intervention (control period), followed by a time period 
with only one of the interventions, and then a time period 
with both interventions. The inclusion of neonates will 
take 2.5 years per PCBC. The sequence and the timing 
at which the PCBC will switch over to the next interven-
tion period will be determined by random allocation. 
The allocation scheme with the possible sequences of 
the interventions is depicted in figure 2. The time blocks 
will take 4 months, except for the first and the last block. 
box 1 the dutch tsb nomogram27
The Dutch total serum bilirubin (TSB) nomogram has the same values as 
the nomogram of the American Academy of Pediatrics. The nomogram 
consists of three risk categories: lower risk, medium risk and higher 
risk. The risk assessment is based on the gestational age and several 
risk factors (blood group antagonism, other haemolytic disease, birth 
asphyxia, suspicion of infection/sepsis, the neonate being ill or drowsy 
and serum albumin level below 30 g/L). The need for phototherapy and 
exchange transfusion depend on the risk assessment and the postnatal 
age of the neonate. A translated version of the Dutch TSB nomogram is 
depicted in figure 1.
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These two blocks will cover 5.5 months, because, to be 
able to make a comparison within a cluster, a sufficient 
number of participants in the control period (C) and in 
the period with both interventions (I1 + I2) should be 
included, even when a smaller PCBC is randomised to 
time line 1 or 6.
A flowchart with an overview of the study procedures 
with the different intervention phases and possible orders 
of intervention phases from the perspective of a partici-
pant is displayed in figure 3.
Primary outcomes
The two interventions each have their own primary 
outcome. The primary outcome for TcB measurement as 
a screening tool for jaundice will be the proportion of 
neonates having severe hyperbilirubinaemia at any time 
point within the first 14 days of life. Severe hyperbiliru-
binaemia is defined as a TSB level above the mean of 
the phototherapy and exchange transfusion thresholds, 
according to the Dutch nomogram9;that is,
  TSB >
phototherapy threshold+exchange transfusion threshold
2   
For the second intervention, phototherapy in the PCBC, 
the primary outcome will be the proportion of neonates 
requiring hospital admission for hyperbilirubinaemia 
treatment within the first 14 days of life. Hyperbilirubi-
naemia treatment will be considered the indication for 
hospital admission if the neonate received phototherapy 
or an exchange transfusion for hyperbilirubinaemia 
within 24 hours after hospital admission.
secondary outcomes
The secondary outcomes will also be assessed within the 
first 14 days of life (except for kernicterus) and are listed 
in table 1.
Cost-effectiveness analysis
A cost-effectiveness analysis (CEA) will be performed 
from the healthcare perspective. In the CEA, the costs 
and outcomes of the interventions, compared with 'usual 
care', will be identified, measured and valued.
For all of the following items, healthcare use will 
be measured: TSB and TcB tests, phototherapy in the 
hospital, phototherapy in the PCBC, exchange transfu-
sions, PCBC and/or hospital admission days and ambu-
lance transportation to a hospital. These data will be 
recorded during the study and/or retrieved from the 
electronic information systems of the participating PCBCs 
and affiliated hospitals.
Then, integral unit prices will be calculated using 
real economic cost prices or using standard cost-prices 
for health economic evaluations.34 Unit prices will be 
multiplied by the quantities for each resource used and 
summed over the separate types of resources to give the 
total cost per patient.
Regarding the outcomes, the CEA will look at the 
number of neonates with severe hyperbilirubinaemia (as 
defined above) and the number of hospital admissions. 
Data on costs and outcomes will be measured throughout 
the 14-day observation period. As the final outcome 
measure of the CEA, incremental cost effectiveness ratios 
Figure 1 Phototherapy and exchange transfusion thresholds for neonates with a gestational age of 35 weeks or more. 
Translated from Dutch. The Dutch nomogram can be downloaded from the website (http://babyzietgeel.nl/kinderarts/
hulpmiddelen/diagnostiek/bilicurve35wkn.php). AS,Apgar score; ET, exchange transfusion; PT, phototherapy; TSB, total serum 
bilirubin.
Figure 2 Allocation scheme. C, control; I1, intervention 1, 
transcutaneous bilirubinometry measurement; I2, intervention 
2, phototherapy in primary care birth centres.
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(ICERs) will calculated, expressed as incremental costs 
per case of severe hyperbilirubinaemia or hospitalisation 
avoided. Uncertainty in the estimation of the ICERs will 
be illustrated through cost-effectiveness planes. Where 
relevant, sensitivity analyses will be performed to assess 
the robustness of the analyses to certain assumptions.
sample size
Two sample size calculations are required since two inter-
ventions, each with their own outcomes, are evaluated. 
The interventions are considered to be independent of 
each other and therefore the larger sample size among 
the two sample size calculations is considered appropriate 
for the entire study. Sample size calculations are based on 
detecting superiority rather than non-inferiority.
The estimated incidence of severe hyperbilirubinaemia 
in term neonates in the Netherlands is 1.2% per year.9 A 
previous study in Canada regarding screening for uncon-
jugated hyperbilirubinaemia using TcB among healthy 
neonates with ≥35 weeks of gestation showed a relative 
reduction of 55% in severe hyperbilirubinaemia following 
implementation.16 We therefore hypothesise that the 
TcB screening intervention will decrease the incidence 
of severe hyperbilirubinaemia from 1.2% to 0.5% (ie, 
by 0.7% points; a relative reduction of 58%). At a power 
of 80% and a two-sided alpha of 0.05, 2691 neonates per 
arm are needed to identify this effect.
The estimated proportion of neonates needing photo-
therapy is 4%.9 We anticipate that approximately 50% of 
the neonates with hyperbilirubinaemia will have an indi-
cation to be admitted to the hospital (eg, feeding diffi-
culties in addition to hyperbilirubinaemia or need for 
intensive phototherapy). Therefore, we hypothesise that 
the planned application of phototherapy in the PCBC 
will decrease the need for hospital admission for hyper-
bilirubinaemia by 2% points (ie, 50% relative reduction). 
At a power of 80% and a two-sided alpha of 0.05, 1136 
neonates per arm are needed to identify this effect. While 
our study is a cluster RCT, given the cross-sectional nature 
of a stepped-wedge design the effect of intracluster 
correlation on power is minimal, therefore we did not 
adjust for intracluster correlation.35
Based on the larger sample size of 2691 neonates per 
arm, 5382 neonates are needed in total. We aim to include 
5500 neonates to account for a degree of missing data.
randomisation and blinding
Each of the participating PCBCs will be randomised to 
one of the predefined timelines (as depicted in figure 2 
above) by an online randomisation module ( www. random-
ization. com). The two smallest PCBCs will be paired and 
randomised to the same timeline (see figure 2).
Given the nature of the treatment in the intervention 
groups and the control group, blinding of participants 
(and parents) and healthcare personnel is not possible. 
Analyses will be performed by a researcher who is blinded 
to the PCBC allocation scheme.
study procedures
All PCBCs in the Netherlands that provide maternity 
care to mothers and neonates in the first days after 
delivery were invited to participate. Eligibility of neonates 
admitted to the PCBC will be assessed by the maternity 
care or study personnel based on the inclusion and 
Figure 3 Flowchart for study inclusion. GA, gestational age; TcB, transcutaneous bilirubinometry; TSB, total serum bilirubin; 
PCBC, primary care birth centres.
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exclusion criteria. IC of parents will be obtained by the 
maternity care professional. Research nurses and study 
personnel will support the maternity care professionals in 
obtaining IC and collecting data.
Depending on the allocation and the moment of admis-
sion in the PCBC during the study period, the neonate is 
included in the control period, in a time period where 
one of the interventions is implemented, or in a time 
period where both interventions are implemented. Stan-
dard operating procedures (SOPs) for each study phase 
have been developed.
Maternity care personnel of all PCBCs will be 
trained in the SOPs and in using the transcutaneous 
bilirubinometer and the phototherapy mattress to 
ensure the interventions are applied in a professional 
standardised manner. For this purpose, an e-learning 
Table 1 Secondary outcomes
Secondary outcomes
Assessed in Outcome Recorded by
All neonates Number of times TcB quantified Maternity care professional
Individual TcB readings Maternity care professional
Highest TSB level Maternity care professional and/or  EMR in 
hospital
Number of neonates having TSB quantified Maternity care professional
Number of times blood taken for TSB quantification Maternity care professional and/or EMR in 
hospital
Individual TSB levels Maternity care professional and/or EMR in 
hospital
Number of times blood taken for TSB quantification before 
start of phototherapy
Maternity care professional and/or EMR in 
hospital
Number of neonates receiving phototherapy Maternity care professional and/or EMR in 
hospital
Duration (hours) of phototherapy Maternity care professional and/or EMR in 
hospital
Number of neonates having TSB level above exchange 
transfusion threshold9
Maternity care professional and/or EMR in 
hospital
Number of neonates who actually received an exchange 
transfusion
EMR in hospital
Number of neonates having kernicterus* EMR in hospital and/or EMR at general 
practitioner
Duration of stay in the PCBC Maternity care professional
Duration of hospital stay following initial PCBC admission 
(if relevant)
EMR in hospital
Number of transfers between PCBCs/hospitals Maternity care professional and parental 
questionnaire
Number of times affiliated paediatrician consulted Maternity care professional
Experience of parents regarding hyperbilirubinaemia 
assessment and treatment
Parental questionnaire
Experience of attending maternity care personnel 
regarding the daily practice of hyperbilirubinaemia 
assessment and treatment during control and 
intervention periods, including facilitators and barriers for 
implementation
Maternity care assistant questionnaire
Within the group included 
in the intervention period 
with phototherapy in the 
PCBC
The number of neonates in whom phototherapy was 
initiated in the hospital, including reasons for this hospital 
admission
EMR in hospital
The number of neonates requiring subsequent hospital 
admission for hyperbilirubinaemia treatment (ie, after 
initiation of phototherapy in the PCBC), including reasons 
for this 'treatment failure'
EMR in hospital
*The diagnosis of kernicterus will be made by combining clinical signs and symptoms and additional investigations (eg, cerebral 
ultrasound, MRI) up to 1 year after birth in every neonate who had a TSB level above the exchange transfusion threshold level.
EMR, electronic  medical record; PCBC, primary care birth centres; TcB, transcutaneous bilirubinometry; TSB, total serum bilirubin. 
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module has been developed (available from: https:// 
xoteur. 12change. eu/ play. php? template_ id= 798); 
in addition, during the study period three training 
sessions for maternity care professionals are held at 
each PCBC prior to the start of each subsequent study 
phase (ie, intervention implementation).
data collection
Data collection at the PCBC will be performed by mater-
nity care personnel. Together with the training for using 
the transcutaneous bilirubinometer and the phototherapy 
mattress, maternity care personnel will be trained in 
adequate data collection. Data collection is described in the 
SOPs as well.
After inclusion, a maternity care professional of the 
PCBC will record baseline characteristics of the mother 
and the neonate (see table 2) using a standardised regis-
tration form at a secured internet page. All participants 
will receive an anonymised study number.
The maternity care professionals will record several 
measurements during PCBC stay. These measurements 
are noted in table 3. All data will be recorded in stan-
dardised case report forms. The study team, the study 
monitor, and (inter)national supervisory authorities will 
have access to the data and the final dataset.
A questionnaire for the parents/caregivers to eval-
uate their experience will be sent by email 14 days after 
the birth of the neonate. This questionnaire will assess 
parental satisfaction, burdensomeness of interventions 
for the neonate and experienced competence of mater-
nity care professionals. If parents do not have access to the 
internet or do not respond to the questionnaire by email, 
they will be approached by regular mail or by phone. The 
community midwife and/or the general practitioner will be 
approached if parents do not respond at all. Both after the 
control and after each intervention period, maternity care 
personnel will be invited to complete a questionnaire about 
their experiences regarding the daily practice of hyperbili-
rubinaemia assessment and treatment during these periods 
(eg, facilitators and barriers for implementation, sense of 
competence regarding applying the new interventions, 
integrating the new interventions in routine care, and the 
content of the training regarding the new interventions).
statistical analysis
We will use cluster-specific methods because randomisa-
tion will be performed at the PCBC level rather than at 
Table 2 Baseline characteristics
Baseline characteristics
Parental characteristics Maternal age
Maternal ethnicity
Maternal blood group
Paternal ethnicity
Presence of haemolytic disease (other than blood group antagonism) in mother or father
Characteristics of 
pregnancy and birth
Parity
Maternal atypical red-cell alloantibodies during pregnancy
Gestational age at birth
Type of delivery: vaginal delivery, vacuum-assisted vaginal delivery, forceps-assisted vaginal delivery, 
caesarean delivery without vacuum or forceps extraction (before or during delivery), caesarean 
delivery with vacuum or forceps extraction (before or during delivery).
Neonatal characteristics Date of birth
Time of birth
Sex
Birth weight (in grams)
Presence of birth trauma
Type of feeding
Neonatal blood group (if known)
Foetal or neonatal Rhesus factor (if known)
Direct antiglobulin (Coombs) test (if known)
Presence of haemolytic disease (other than blood group antagonism)
Presence of birth asphyxia: Apgar score <5 at 5 min or pH <7.0 in umbilical cord blood
Suspicion of sepsis
Neonate being ill or drowsy
Other characteristics Siblings who experienced neonatal hyperbilirubinaemia (and cause of hyperbilirubinaemia, if known)
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the individual level. For both primary objectives, an inten-
tion-to-treat analysis will be performed.
To evaluate whether the occurrence of the primary 
outcomes of both interventions are different between 
the study periods with and without the intervention(s), 
generalised linear mixed models (GLMMs) will be used. 
GLMMs account for the systematically different observa-
tion periods and for clustering in the data.36 In case of 
missing data, multiple imputation using chained equa-
tions will be used. Relative risks, risk differences, and rela-
tive risk reduction with corresponding 95% CIs will be 
calculated from the GLMMs.
Subgroup analyses to evaluate the effect of the interven-
tions in neonates of different ethnicities (Caucasian and 
non-Caucasian) and different GA groups (<38 weeks of 
gestation and ≥38 weeks of gestation) will be performed.
We will perform a per-protocol analysis to assess the 
impact of potential contamination during the first days of 
a new intervention period as a sensitivity analysis in addi-
tion to the intention-to-treat analysis.
safety
Adverse events noticed by parents or maternity care 
professionals will be recorded in the case report forms by 
the maternity care assistant or study personnel. Serious 
adverse events will be communicated to the study team 
within 4 days. The study team will investigate this event 
and report it to the sponsor and the Medical Research 
Ethics Committee of the Erasmus MC Rotterdam. Insur-
ance has been taken out for every participant in this study. 
The insurance covers any damage caused by the study.
The medical technical service department of the 
Erasmus MC-Sophia will provide technical maintenance 
of the phototherapy mattresses (at least two times per 
year). Once a year, calibration of the TcB devices will be 
carried out by the manufacturer.
A Data Safety Monitoring Board will not be estab-
lished, given that the risks of this study are considered 
negligible. Monitoring of the study will be carried out 
according to the Guideline for Good Clinical Practice by 
an independent, qualified monitor at least once a year 
per PCBC.37
Patient and public involvement
The study protocol, study procedures and patient informa-
tion form were discussed with the regional patient involve-
ment board of the Rijnmond Obstetric District Platform 
('District Verloskundig Platform'; DVP) and patient repre-
sentatives of the Child & Hospital foundation ('Stichting 
Kind & Ziekenhuis': https://www. kindenziekenhuis. nl/). 
They consider the project highly relevant from a patient 
perspective and have agreed to be involved throughout 
execution, analysis and interpretation, dissemination to 
patients and implementation. The involved patient panels 
have considered the burden of the interventions negligible 
and underline the potential benefits of the study.
Ethics and dissemination
 Collected data will be coded. Only investigators will have 
access to the identification list. Study documents and data 
will be stored for 15 years after completion of the study.
The full protocol will be shared at request. Results of 
this study including the statistical code will be published 
in peer reviewed scientific journals and be presented at 
(inter)national meetings. The results of the study will 
be reported according to the Consolidated Standards of 
Reporting Trials Statement guidelines.38 We intend to 
provide an anonymised version of the dataset at request. 
Authorship will be determined according to the guide-
lines of the International Committee of Medical Journal 
Editors.39 No professional writers will be used.
dIsCussIon
Identification and (referral for) treatment of neonatal 
jaundice is daily practice for maternity care professionals. 
The continuing occurrence and devastating consequences 
of KSD underline the urgent need for more effective 
identification and treatment of at-risk neonates.1 7 This 
pragmatic study aims to evaluate the (cost) effectiveness 
Table 3 Daily measurements in PCBC
Daily measurements
Control period Skin colour: pink, slightly yellow, moderately yellow, quite yellow, very 
yellow
Weight (in grams)
Risk factors for hyperbilirubinaemia (if present)
TSB values with date and time of measurement (if relevant)
Decisions made based on TSB (if relevant)
Period with TcB screening (extra measurements in 
addition to control period)
TcB values measured at forehead and sternum together with date and 
time of measurement
(once a day or two times if indicated)
Phototherapy in PCBC (extra measurements in 
addition to control period)
Start and end date and time of phototherapy
Decisions made by the affiliated paediatrician regarding phototherapy
PCBC, primary care birth centres; TcB, transcutaneous bilirubinometry ; TSB, total serum bilirubin. 
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of (1) TcB measurement as a screening tool for jaundice 
in a primary care setting and (2) application of photo-
therapy in the PCBCs in the Netherlands. To the best 
of our knowledge, this RCT will be the first to assess the 
(cost) effectiveness of these diagnostic and treatment 
modalities in a primary care setting.
The study design allows all participating PCBCs to 
implement both interventions during the study and as 
such all PCBCs will have implemented the interventions 
as standard care toward the end of the study. This process 
will provide valuable information about the facilitators 
and barriers for implementation that will help upscaling 
of the interventions if (cost)effectiveness is confirmed.
A limitation of this study is that parents and care 
providers cannot practically be blinded to allocation of 
the interventions. As a result, maternity care personnel 
or paediatricians may act differently in control and inter-
vention periods. We will try to identify this via the ques-
tionnaires addressed at the maternity care assistants and 
the recording of the underlying reasons for paediatri-
cians to divert from the new practice of applying photo-
therapy in the PCBC, if relevant. We will, furthermore, 
record the number of times TSB is quantified to evaluate 
whether this may change following implementation of 
the screening programme.
For this study we take advantage of the fact that neonates 
receive primary care within PCBCs rather than at home. 
This centralised primary care provision is efficient in 
terms of feasibility of training the maternity care profes-
sionals and of minimising costs of transcutaneous biliru-
binometers and phototherapy mattresses (ie, groups of 
neonates can be covered with individual devices). More-
over, although the Dutch perinatal healthcare system is 
quite unique, care provision in PCBCs in the Netherlands 
is comparable to regular maternity care in many other 
high-income countries, which promotes generalisability.
We expect the interventions to be similarly effective in 
the home setting as in the PCBC setting, since the popu-
lation in the PCBCs in the Netherlands does not differ 
from that of the home setting. The costs in the PCBC 
setting may however differ from the home setting. Gener-
alisability of the results to other countries and the home 
settings depends on several aspects, such as characteris-
tics of the population, organisation of the maternity care 
system, presence of an effective screening programme for 
neonatal hyperbilirubinaemia and proximity and avail-
ability of sufficient healthcare. A future study to investi-
gate the feasibility and effectiveness of the interventions 
in the home setting is needed if the current study is 
successful.
In conclusion, our study will generate useful data about 
the (cost)effectiveness of TcB measurement as a universal 
screening tool for jaundice, potentially reducing the inci-
dence of severe neonatal hyperbilirubinaemia. Several 
guidelines have highlighted the lack of research into 
the prevention of severe hyperbilirubinaemia.9 10 13 40 
Although most of these guidelines do not specify where 
phototherapy should be instituted, it is standard practice 
in most high-income countries, including the Nether-
lands, to do so in the hospital setting.9 10 40 As such, insti-
tution of phototherapy in the primary care setting has 
significant potential to reduce healthcare costs associated 
with hospital admission. Furthermore, it promotes moth-
er-child bonding by allowing mother and child to remain 
together in the same location.
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